CN120058723A - 喜树碱类化合物及其制备方法和应用 - Google Patents
喜树碱类化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN120058723A CN120058723A CN202510232225.8A CN202510232225A CN120058723A CN 120058723 A CN120058723 A CN 120058723A CN 202510232225 A CN202510232225 A CN 202510232225A CN 120058723 A CN120058723 A CN 120058723A
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- formula
- hydrogen
- mobile phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021101599566 | 2021-02-05 | ||
| CN202110159956 | 2021-02-05 | ||
| CN2021105333044 | 2021-05-17 | ||
| CN202110533304 | 2021-05-17 | ||
| CN202110718245 | 2021-06-28 | ||
| CN2021107182458 | 2021-06-28 | ||
| CN202110936768X | 2021-08-16 | ||
| CN202110936768 | 2021-08-16 | ||
| CN2021113553309 | 2021-11-16 | ||
| CN202111355330 | 2021-11-16 | ||
| PCT/CN2022/074328 WO2022166762A1 (zh) | 2021-02-05 | 2022-01-27 | 喜树碱类化合物及其制备方法和应用 |
| CN202280008418.XA CN116829561A (zh) | 2021-02-05 | 2022-01-27 | 喜树碱类化合物及其制备方法和应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280008418.XA Division CN116829561A (zh) | 2021-02-05 | 2022-01-27 | 喜树碱类化合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120058723A true CN120058723A (zh) | 2025-05-30 |
Family
ID=82741966
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510232225.8A Pending CN120058723A (zh) | 2021-02-05 | 2022-01-27 | 喜树碱类化合物及其制备方法和应用 |
| CN202280008418.XA Pending CN116829561A (zh) | 2021-02-05 | 2022-01-27 | 喜树碱类化合物及其制备方法和应用 |
| CN202311518671.2A Active CN117567478B (zh) | 2021-02-05 | 2022-01-27 | 喜树碱类化合物及其制备方法和应用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280008418.XA Pending CN116829561A (zh) | 2021-02-05 | 2022-01-27 | 喜树碱类化合物及其制备方法和应用 |
| CN202311518671.2A Active CN117567478B (zh) | 2021-02-05 | 2022-01-27 | 喜树碱类化合物及其制备方法和应用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20240158410A1 (https=) |
| EP (3) | EP4628165A3 (https=) |
| JP (3) | JP7821188B2 (https=) |
| KR (3) | KR20250119655A (https=) |
| CN (3) | CN120058723A (https=) |
| AU (1) | AU2022216696A1 (https=) |
| CA (1) | CA3209426A1 (https=) |
| MX (1) | MX2023008716A (https=) |
| WO (1) | WO2022166762A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023551355A (ja) | 2020-09-30 | 2023-12-08 | デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド | 抗腫瘍化合物並びにその調製方法及び使用 |
| US20250276078A1 (en) * | 2020-10-12 | 2025-09-04 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Camptothecin Derivative And Ligand-drug Conjugate Thereof |
| EP4628165A3 (en) * | 2021-02-05 | 2026-03-11 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| JP2024532768A (ja) * | 2021-08-19 | 2024-09-10 | ハイナン シムセレ ザイミン ファーマシューティカル カンパニー リミテッド | カンプトテシン誘導体、その薬物組成物およびその応用 |
| CN118119594A (zh) * | 2021-10-26 | 2024-05-31 | 上海弼领生物技术有限公司 | 一种喜树碱类衍生物中间体、其制备方法和用途 |
| WO2023083381A1 (zh) | 2021-11-15 | 2023-05-19 | 成都百利多特生物药业有限责任公司 | 双特异性抗体-喜树碱类药物偶联物及其医药用途 |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| CN118696048A (zh) * | 2022-05-09 | 2024-09-24 | 同宜医药（苏州）有限公司 | 一种喜树碱衍生物，基于其的抗体-药物偶联物和药物组合物，及其应用 |
| JP2025515988A (ja) | 2022-05-13 | 2025-05-23 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | カンプトテシン化合物、その調製方法及びその使用 |
| IL318296A (en) | 2022-07-15 | 2025-03-01 | Genequantum Healthcare Suzhou Co Ltd | Anti-TROP2 antibody and its conjugate |
| EP4562051A1 (en) * | 2022-07-26 | 2025-06-04 | Immunome, Inc. | Immunoconjugates and methods |
| US20240116945A1 (en) * | 2022-09-02 | 2024-04-11 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
| CN121064210A (zh) * | 2022-09-09 | 2025-12-05 | 杭州爱科瑞思生物医药有限公司 | 喜树碱-7-乙基胺衍生物及其制备方法和应用 |
| KR20250069963A (ko) * | 2022-09-30 | 2025-05-20 | 베이진 스위찰랜드 게엠베하 | 엑사테칸 유사체의 리간드-약물 접합체 및 이의 의학적 용도 |
| WO2024078449A1 (en) | 2022-10-09 | 2024-04-18 | LaNova Medicines Limited | Compounds, compositions and methods |
| WO2024091437A1 (en) * | 2022-10-25 | 2024-05-02 | Merck Sharp & Dohme Llc | Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| WO2024114318A1 (zh) * | 2022-11-29 | 2024-06-06 | 四川科伦博泰生物医药股份有限公司 | 药物连接子化合物及其制备方法和用途 |
| CN116870187A (zh) * | 2022-12-29 | 2023-10-13 | 杭州爱科瑞思生物医药有限公司 | N-氧杂环烷基取代的喜树碱衍生物的抗体偶联药物 |
| CN116712562A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | N-叠氮烷基取代的喜树碱衍生物的抗体偶联药物 |
| CN116712563A (zh) * | 2022-12-29 | 2023-09-08 | 杭州爱科瑞思生物医药有限公司 | N-卤代烷基取代的喜树碱衍生物的抗体偶联药物 |
| EP4655006A2 (en) * | 2023-01-25 | 2025-12-03 | Immunome, Inc. | Exatecan immunoconjugates |
| CN119630672B (zh) * | 2023-02-23 | 2026-01-30 | 一线医药（杭州）有限公司 | 喜树碱衍生物及其偶联物以及其制备方法和医药用途 |
| TW202502774A (zh) * | 2023-03-01 | 2025-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種茚并［１，２－ｂ］喹啉－１０，１３－二酮衍生物的製備方法 |
| WO2024208314A1 (zh) * | 2023-04-07 | 2024-10-10 | 长春金赛药业有限责任公司 | 喜树碱衍生物、药物组合物及其制备方法和应用 |
| CN116478051B (zh) * | 2023-04-13 | 2024-06-21 | 戊言医药科技（上海）有限公司 | 一种贝洛替康盐酸盐及其关键中间体的制备方法 |
| WO2024227432A1 (zh) * | 2023-04-30 | 2024-11-07 | 泰诚思(上海)生物医药有限公司 | 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用 |
| WO2024227439A1 (zh) * | 2023-05-04 | 2024-11-07 | 四川科伦博泰生物医药股份有限公司 | 具有靶向作用的偶联物及其制备方法和用途 |
| CN117417346B (zh) * | 2023-09-11 | 2025-07-25 | 常州合全药业有限公司 | 喜树碱类衍生物的制备方法 |
| KR20250059577A (ko) | 2023-10-24 | 2025-05-07 | 삼성디스플레이 주식회사 | 표시 장치 |
| TW202527997A (zh) * | 2023-11-15 | 2025-07-16 | 大陸商四川科倫博泰生物醫藥股份有限公司 | 靶向ｅｇｆｒ／ｃ—ｍｅｔ之抗體—藥物結合物以及其製備方法及用途 |
| CN120058720A (zh) * | 2024-01-08 | 2025-05-30 | 杭州爱科瑞思生物医药有限公司 | 7-含羟胺结构取代的烷基喜树碱衍生物的制备及其应用 |
| CN120058721A (zh) * | 2024-01-08 | 2025-05-30 | 杭州爱科瑞思生物医药有限公司 | 7-氟烷基取代的喜树碱衍生物的制备及其应用 |
| WO2025162049A1 (zh) * | 2024-02-02 | 2025-08-07 | 长春金赛药业有限责任公司 | 卤代烯烃类喜树碱衍生物、药物组合物及其制备方法和应用 |
| WO2025242090A1 (zh) * | 2024-05-21 | 2025-11-27 | 康诺亚生物医药科技（成都）有限公司 | 喜树碱衍生物及其中间体的制备方法 |
| WO2026046398A1 (en) * | 2024-08-30 | 2026-03-05 | Hansoh Bio Llc | Novel camptothecin derivative and conjugate thereof, preparation method therefor and application thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3008226B2 (ja) * | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| DE69623961T2 (de) * | 1995-06-21 | 2003-05-08 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Paris | Camptothecinanaloge, verfahren zur ihrer herstellung, ihre verwendungals arzneimittel und diese enthaltende pharmazeutische zusammenfassungen |
| CA2192725C (en) * | 1995-12-28 | 2004-04-20 | Kenji Tsujihara | Camptothecin derivatives |
| CN100408582C (zh) * | 2004-02-12 | 2008-08-06 | 中国人民解放军第二军医大学 | 高喜树碱类化合物及其制备方法和用途 |
| JP2019515025A (ja) * | 2016-04-04 | 2019-06-06 | ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー | トポイソメラーゼ毒 |
| CN110891942B (zh) * | 2017-07-14 | 2022-06-07 | 四川科伦博泰生物医药股份有限公司 | 噁二唑类衍生物、其制备方法及其在医药上的应用 |
| CN119241554A (zh) * | 2017-12-15 | 2025-01-03 | 四川科伦博泰生物医药股份有限公司 | 生物活性物偶联物及其制备方法和用途 |
| BR112020020466A2 (pt) | 2018-04-06 | 2021-01-12 | Seattle Genetics, Inc. | Conjugados de peptídeo de camptotecina |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| WO2020063676A1 (zh) * | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
| CA3114474A1 (en) * | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
| MX2021011812A (es) * | 2019-03-29 | 2021-10-22 | Medimmune Ltd | Compuestos y conjugados de estos. |
| SG11202110922QA (en) | 2019-04-26 | 2021-10-28 | Immunogen Inc | Camptothecin derivatives |
| CN111689980A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种喜树碱药物及其抗体偶联物 |
| CN110357897A (zh) * | 2019-07-26 | 2019-10-22 | 上海健康医学院 | 一种具有抗肿瘤活性的喜树碱衍生物及其制备方法和应用 |
| CN112125915A (zh) * | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
| JP7781064B2 (ja) * | 2020-01-22 | 2025-12-05 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｔｒｏｐ－２抗体－エキサテカン類似体複合体及びその医薬用途 |
| AU2021289927A1 (en) * | 2020-06-08 | 2023-01-19 | Systimmune, Inc. | Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof |
| JP7753372B2 (ja) * | 2020-10-12 | 2025-10-14 | シーチュアン バイリ ファーム シーオー． エルティーディー | 重水素化カンプトテシン系誘導体及びその抗体薬物複合体 |
| EP4628165A3 (en) * | 2021-02-05 | 2026-03-11 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Camptothecin compound, preparation method therefor, and application thereof |
| CN117255790A (zh) * | 2021-06-02 | 2023-12-19 | 四川科伦博泰生物医药股份有限公司 | 一类化学偶联连接子及其用途 |
| JP2024521629A (ja) * | 2021-06-02 | 2024-06-04 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | 抗体薬物コンジュゲート、及びその調製方法及びその使用 |
| US11814394B2 (en) * | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| CN117567487A (zh) * | 2023-11-27 | 2024-02-20 | 金宏气体股份有限公司 | 双核Ag(I)配合物晶体、制备方法、负载物、装置及应用 |
-
2022
- 2022-01-27 EP EP25191607.8A patent/EP4628165A3/en active Pending
- 2022-01-27 US US18/262,821 patent/US20240158410A1/en active Pending
- 2022-01-27 AU AU2022216696A patent/AU2022216696A1/en active Pending
- 2022-01-27 EP EP25191605.2A patent/EP4613335A3/en active Pending
- 2022-01-27 KR KR1020257024904A patent/KR20250119655A/ko active Pending
- 2022-01-27 CN CN202510232225.8A patent/CN120058723A/zh active Pending
- 2022-01-27 CN CN202280008418.XA patent/CN116829561A/zh active Pending
- 2022-01-27 JP JP2023544762A patent/JP7821188B2/ja active Active
- 2022-01-27 EP EP22749041.4A patent/EP4289851A4/en active Pending
- 2022-01-27 CA CA3209426A patent/CA3209426A1/en active Pending
- 2022-01-27 MX MX2023008716A patent/MX2023008716A/es unknown
- 2022-01-27 WO PCT/CN2022/074328 patent/WO2022166762A1/zh not_active Ceased
- 2022-01-27 KR KR1020257024905A patent/KR20250120438A/ko active Pending
- 2022-01-27 KR KR1020237025527A patent/KR20230142710A/ko active Pending
- 2022-01-27 CN CN202311518671.2A patent/CN117567478B/zh active Active
-
2025
- 2025-07-24 JP JP2025123923A patent/JP2025160318A/ja active Pending
- 2025-07-24 JP JP2025123921A patent/JP2025160317A/ja active Pending
- 2025-07-24 US US19/279,242 patent/US20250346606A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025160317A (ja) | 2025-10-22 |
| KR20250119655A (ko) | 2025-08-07 |
| EP4628165A2 (en) | 2025-10-08 |
| JP2024506819A (ja) | 2024-02-15 |
| EP4289851A4 (en) | 2025-10-15 |
| MX2023008716A (es) | 2023-08-02 |
| CN117567478A (zh) | 2024-02-20 |
| CN117567478B (zh) | 2025-03-21 |
| EP4613335A3 (en) | 2025-12-10 |
| KR20230142710A (ko) | 2023-10-11 |
| EP4628165A3 (en) | 2026-03-11 |
| US20240158410A1 (en) | 2024-05-16 |
| JP7821188B2 (ja) | 2026-02-26 |
| JP2025160318A (ja) | 2025-10-22 |
| KR20250120438A (ko) | 2025-08-08 |
| CN116829561A (zh) | 2023-09-29 |
| US20250346606A1 (en) | 2025-11-13 |
| EP4613335A2 (en) | 2025-09-10 |
| WO2022166762A1 (zh) | 2022-08-11 |
| AU2022216696A1 (en) | 2023-08-17 |
| EP4289851A1 (en) | 2023-12-13 |
| CA3209426A1 (en) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117567478B (zh) | 喜树碱类化合物及其制备方法和应用 | |
| CN116249683B (zh) | 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用 | |
| CN116113632B (zh) | 杂环类衍生物、其制备方法及其医药上的用途 | |
| JP2025515988A (ja) | カンプトテシン化合物、その調製方法及びその使用 | |
| CN116406363B (zh) | 四环类衍生物、其制备方法及其医药上的用途 | |
| CN112745335A (zh) | 一种三并杂环化合物及其用途 | |
| CN116113416B (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| CN112300153A (zh) | 一种杂环化合物、药物组合物和用途 | |
| CN116157400B (zh) | 杂环类衍生物及其制备方法和用途 | |
| KR20210141461A (ko) | 이미다조퀴놀린 아민 유도체, 약제학적 조성물, 이의 용도 | |
| WO2013091507A1 (zh) | 杂环胺基烷氧基取代的喹唑啉衍生物及其用途 | |
| CN113929681A (zh) | 四环类衍生物及其制备方法和用途 | |
| WO2025036489A1 (zh) | 一种氰基芳香环衍生物及其在医药上的应用 | |
| CN112341477A (zh) | 含有并环基团的咪唑并嘧啶类化合物、其制备方法及用途 | |
| JP2024508426A (ja) | 免疫調節物質及び免疫調節物質コンジュゲート | |
| EP3216799A1 (en) | New type of cytidine derivative dimer and application thereof | |
| HK40101679A (zh) | 喜树碱类化合物及其制备方法和应用 | |
| HK40101679B (zh) | 喜树碱类化合物及其制备方法和应用 | |
| EP4219453A1 (en) | Pyrazole compound and preparation method therefor and use thereof | |
| JP2024517867A (ja) | Ｗｄｒ５阻害剤およびモジュレーター | |
| CN120858098A (zh) | 稠环化合物及其制备方法和应用 | |
| CN112996784B (zh) | 吲哚衍生物及其在医药上的应用 | |
| Vitkovska et al. | Appendix IV–MACROCYCLIC TUBULIN POLYMERIZATION INHIBITORS AS ANTICANCER AGENTS | |
| WO2025214344A1 (zh) | 一种kras抑制剂及其在药学上的应用 | |
| HK40068190A (en) | Imidazoquinoline amine derivatives, pharmaceutical compositions and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |